ClinConnect ClinConnect Logo
Search / Trial NCT05943002

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia

Launched by GERMAN CENTER FOR NEURODEGENERATIVE DISEASES (DZNE) · Jul 5, 2023

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Health Related Quality Of Life Economic Evaluation Psychosocial Health Mobile Health App Friedreich's Ataxia Ambulatory Assessment

ClinConnect Summary

The PROFA study is a research project looking into the experiences of people living with Friedreich Ataxia (FA), a rare genetic condition that affects movement and coordination. The goal of the study is to understand how FA impacts daily life, including mental health and economic factors. To participate, you must be diagnosed with FA through genetic testing, have a certain level of movement difficulty, and be over the age of 12. You will need access to a smartphone or tablet to take part in the study.

If you join the study, you will first meet with researchers for an interview at one of the study centers in Germany, Austria, or France. After that, you’ll use a mobile app to share your experiences daily to monthly for six months. This research is important because it will provide valuable insights into the challenges faced by individuals with FA, helping to improve support and resources for those affected by the condition. The study is currently recruiting participants, and everyone is welcome to apply.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • FA confirmed by molecular genetic testing
  • Ataxia severity of ≤30 points according to the Scale of the Assessment and Rating of Ataxia (SARA)
  • Access to a smartphone or tablet and able to operate the device
  • Older than 12 years
  • Exclusion Criteria:
  • Lack of ability to give consent
  • Ataxia severity \>30 according to the Scale of the Assessment and Rating of Ataxia (SARA)

About German Center For Neurodegenerative Diseases (Dzne)

The German Center for Neurodegenerative Diseases (DZNE) is a leading research institution dedicated to understanding and combating neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Established to foster innovative research and collaboration, the DZNE integrates clinical and basic research to translate scientific discoveries into effective therapeutic strategies. With a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to advancing knowledge in neurodegeneration, the DZNE actively participates in clinical trials aimed at improving patient outcomes and enhancing the understanding of these complex diseases.

Locations

Innsbruck, , Austria

Paris, , France

Aachen, , Germany

Bonn, , Germany

Münich, , Germany

Tübingen, , Germany

Patients applied

0 patients applied

Trial Officials

Bernhard Michalowsky, PD Dr.

Principal Investigator

German Center for Neurodegenerative Diseases (DZNE) Rostock/ Greifswald, Germany

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported